These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38247385)

  • 1. Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods.
    Anolli MP; Renteria SU; Degasperi E; Borghi M; Facchetti F; Sambarino D; Perbellini R; Monico S; Ceriotti F; Lampertico P
    Liver Int; 2024 Mar; 44(3):831-837. PubMed ID: 38247385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
    Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
    J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study.
    Stelzl E; Ciesek S; Cornberg M; Maasoumy B; Heim A; Chudy M; Olivero A; Miklau FN; Nickel A; Reinhardt A; Dietzsch M; Kessler HH
    J Clin Virol; 2021 Sep; 142():104932. PubMed ID: 34333392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease.
    Palom A; Sopena S; Riveiro-Barciela M; Carvalho-Gomes A; Madejón A; Rodriguez-Tajes S; Roade L; García-Eliz M; García-Samaniego J; Lens S; Berenguer-Hayme M; Rodríguez-Frías F; Hernandez-Évole H; Isabel Gil-García A; Barreira A; Esteban R; Buti M
    Aliment Pharmacol Ther; 2021 Aug; 54(4):462-469. PubMed ID: 34181772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
    Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
    Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.
    Bremer B; Anastasiou OE; Ciesek S; Wedemeyer H
    Antivir Ther; 2019; 24(2):117-123. PubMed ID: 30516520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
    Sandmann L; Deterding K; Bremer B; Port K; Cornberg M; Wedemeyer H; Maasoumy B
    J Viral Hepat; 2023 Apr; 30(4):283-286. PubMed ID: 36648369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Degasperi E; Anolli MP; Sambarino D; Facchetti F; Borghi M; Perbellini R; Monico S; Lampertico P
    J Hepatol; 2024 Jun; ():. PubMed ID: 38901675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
    Hollnberger J; Liu Y; Xu S; Chang S; Martin R; Manhas S; Aeschbacher T; Han B; Yazdi T; May L; Han D; Shornikov A; Flaherty J; Manuilov D; Suri V; Asselah T; Lampertico P; Wedemeyer H; Aleman S; Richards C; Mateo R; Maiorova E; Cihlar T; Mo H; Urban S
    J Hepatol; 2023 Sep; 79(3):657-665. PubMed ID: 37120031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
    Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
    J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
    Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
    Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring.
    Illescas-López M; Chaves-Blanco L; de Salazar A; Hernández-Febles M; Carracedo R; Lagarejos E; Fuentes A; Pereira S; Cea M; De La Iglesia A; Freyre C; Iborra A; Odero V; García-Barrionuevo A; Aguilera A; Pena MJ; García F
    Front Cell Infect Microbiol; 2024; 14():1422299. PubMed ID: 38988808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.
    Deterding K; Xu C; Port K; Dietz-Fricke C; Xun J; Maasoumy B; Cornberg M; Wedemeyer H
    J Viral Hepat; 2023 Jul; 30(7):597-606. PubMed ID: 36924318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.
    Spaan M; Carey I; Bruce M; Shang D; Horner M; Dusheiko G; Agarwal K
    J Hepatol; 2020 Jun; 72(6):1097-1104. PubMed ID: 31981726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype.
    Madejón A; Romero M; Hernández Á; García-Sánchez A; Sánchez-Carrillo M; Olveira A; García-Samaniego J
    World J Gastroenterol; 2016 Mar; 22(11):3165-74. PubMed ID: 27003993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
    Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
    Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir treatment of chronic hepatitis D.
    Kabaçam G; Onder FO; Yakut M; Seven G; Karatayli SC; Karatayli E; Savas B; Idilman R; Bozdayi AM; Yurdaydin C
    Clin Infect Dis; 2012 Sep; 55(5):645-50. PubMed ID: 22573857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
    Nkongolo S; Hollnberger J; Urban S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.